|
|
Article: Cytokinetics Announces Initiation of Phase II Clinical Trial in Renal Cell Cancer and Phase I Clinical Trial in Pediatric Solid Tumors.
- Article from:
- PR Newswire
- Article date:
- December 20, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Cytokinetics Provides Update on Ispinesib Clinical Trials Progress
SOUTH SAN FRANCISCO, Calif., Dec. 20 /PRNewswire-FirstCall/ -- Cytokinetics, Incorporated announced today that the National Cancer Institute (NCI) has initiated a Phase II clinical trial to evaluate the potential efficacy of the kinesin spindle protein (KSP) inhibitor, ispinesib (SB-715992), as a second-line treatment for patients with renal cell cancer and a Phase I clinical trial to evaluate ispinesib as a monotherapy in pediatric patients with relapsed or refractory solid tumors. The NCI is sponsoring these trials as a part of a clinical development program to evaluate the safety and efficacy ...